Clinical responses to oncogene inhibitors result from direct effects on cell-intrinsic growth signals and disruption of downstream messages that produce a protumor immunosuppressive microenvironment. Combining oncogene-targeted and immunomodulatory therapies may result in synergistic effects, producing increased response rates and longer periods of tumor control than can be achieved with either...

s not provided. [14.30–14.50] Tolerogenic properties of anti-alpha/beta T Cell receptor monoclonal antibody in face transplant model Aleksandra Klimczak, Mehmet Unal, Yavuz Demir

Immunomodulating drugs are important tools in the treatment of infectious diseases, especially hepatitis. The authors present different classes of immunomodulators that are currently in use. After the era of antibiotherapy and of augmentation of host defense through immunizations, the time has come for immunomodulation substances to be reevaluated. Becausemultidrug antibiotic resistance has tur...

Treatment of multidrug-resistant tuberculosis (MDR-TB) is extremely challenging due to the virulence of the etiologic strains of Mycobacterium tuberculosis (M. tb), the aberrant host immune responses and the diminishing treatment options with TB drugs. New treatment regimens incorporating therapeutics targeting both M. tb and host factors are urgently needed to improve the clinical management o...

Standard cancer treatments trigger immune responses that may influence tumor control. The nature of these responses varies depending on the tumor and the treatment modality. We previously reported that radiation and androgen-deprivation therapy (ADT) induce tumor-associated autoantibody responses in prostate cancer patients. This follow-up analysis was conducted to assess the relationship betwe...

Although unlikely to replace current standard of care therapies, immunotherapy is emerging as a critical component of breast cancer treatment. Despite initial setbacks, clinical benefit is now evident through immunomodulation and cancer vaccines. Over the past decade, passive immunotherapeutic strategies such as anti-HER2 monoclonal antibody (mAb) therapy have significantly improved the prognos...

Both the increasing number of immunocompromised patients susceptible to pneumonia and the development of bacterial resistance are significant problems related to the treatment of pneumonia. The primary outcome of treatment for pneumonia is to tip the balance towards a successful host response. An ideal approach would be a combination of immunomodulation and conventional antimicrobial therapy. I...